ANKE BIO(SZ:300009) Zheng Quan Zhi Xing·2025-08-21 11:18Core Viewpoint - Anhui Anke Biotechnology (Group) Co., Ltd. has announced the repurchase and cancellation of 276,500 restricted stocks from its third phase incentive plan due to 15 incentive targets no longer meeting the incentive conditions [1][4][11]. Summary by Relevant Sections Announcement of Repurchase - The company held a board meeting on August 20, 2025, where it approved the repurchase of restricted stocks that do not meet incentive conditions, totaling 276,500 shares, which accounts for 0.02% of the company's total share capital [1][4]. - The repurchase includes 174,000 shares from the initial grant and 102,500 shares from the reserved grant [1][4]. Approval Process - The third phase incentive plan underwent necessary approval procedures, including independent opinions from the board and verification by the supervisory board [1][2][3]. - The company disclosed the list of incentive targets and did not receive any objections during the public notice period [2][3]. Repurchase Details - The repurchase price for the initial grant is set at 4.81 yuan per share, while the reserved grant is set at 5.27 yuan per share [4][10]. - The total funds used for the repurchase amount to 1,377,115.00 yuan, sourced from the company's own funds [4][10]. Impact on Company Structure - Following the repurchase, the company's total share capital will decrease by 276,500 shares, with no significant impact on the company's operational performance or management diligence [10][11]. - The total share capital before the repurchase was 1,672,521,258 shares, which will be reduced to 1,672,244,758 shares post-repurchase [10]. Opinions from Committees - The Compensation and Assessment Committee and the Supervisory Board have both expressed their agreement with the repurchase, confirming it aligns with relevant regulations and does not harm the interests of the company or its shareholders [11][11].